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Summary
Background Many infants admitted to hospital undergo repeated invasive procedures. Oral sucrose is frequently given 
to relieve procedural pain in neonates on the basis of its eﬀ ect on behavioural and physiological pain scores. We 
assessed whether sucrose administration reduces pain-speciﬁ c brain and spinal cord activity after an acute noxious 
procedure in newborn infants.
Methods In this double-blind, randomised controlled trial, 59 newborn infants at University College Hospital (London, 
UK) were randomly assigned to receive 0·5 mL 24% sucrose solution or 0·5 mL sterile water 2 min before undergoing 
a clinically required heel lance. Randomisation was by a computer-generated randomisation code, and researchers, 
clinicians, participants, and parents were masked to the identity of the solutions. The primary outcome was pain-
speciﬁ c brain activity evoked by one time-locked heel lance, recorded with electroencephalography and identiﬁ ed by 
principal component analysis. Secondary measures were baseline behavioural and physiological measures, 
observational pain scores (PIPP), and spinal nociceptive reﬂ ex withdrawal activity. Data were analysed per protocol. 
This study is registered, number ISRCTN78390996.
Findings 29 infants were assigned to receive sucrose and 30 to sterilised water; 20 and 24 infants, respectively, were 
included in the analysis of the primary outcome measure. Nociceptive brain activity after the noxious heel lance did 
not diﬀ er signiﬁ cantly between infants who received sucrose and those who received sterile water (sucrose: mean 0·10, 
95% CI 0·04–0·16; sterile water: mean 0·08, 0·04–0·12; p=0·46). No signiﬁ cant diﬀ erence was recorded between the 
sucrose and sterile water groups in the magnitude or latency of the spinal nociceptive reﬂ ex withdrawal recorded 
from the biceps femoris of the stimulated leg. The PIPP score was signiﬁ cantly lower in infants given sucrose than in 
those given sterile water (mean 5·8, 95% CI 3·7–7·8 vs 8·5, 7·3–9·8; p=0·02) and signiﬁ cantly more infants had no 
change in facial expression after sucrose administration (seven of 20 [35%] vs none of 24; p<0·0001).
Interpretation Our data suggest that oral sucrose does not signiﬁ cantly aﬀ ect activity in neonatal brain or spinal cord 
nociceptive circuits, and therefore might not be an eﬀ ective analgesic drug. The ability of sucrose to reduce clinical 
observational scores after noxious events in newborn infants should not be interpreted as pain relief.
Funding Medical Research Council.
Introduction
International clinical guidelines recommend that oral 
sucrose is given to relieve procedural pain in neonates.1 
These recommendations are based on results from 
several randomised controlled clinical trials that conclude 
that sucrose is eﬀ ective in reducing pain in preterm and 
term neonates.2 Because many infants admitted to 
hospital undergo repeated invasive procedures,3,4 and 
because there is increasing evidence of short-term and 
long-term adverse neurodevelopmental consequences,5–9 
assessment of the eﬀ ectiveness of sucrose analgesia in 
this patient group is essential. As a result, 44 randomised 
controlled trials investigating the eﬀ ectiveness of sucrose 
analgesia in newborn infants are included in a recent 
Cochrane Review.2 
A major challenge in analgesic trials in the infant 
population is deﬁ nition of a reliable, quantitative 
outcome measurement of pain because verbal reports 
and visual analogue scales cannot be used.5,10 The most 
commonly used outcome measures are based on 
behavioural and physiological observations, and many 
validated composite pain measurement instruments, 
such as the premature infant pain proﬁ le (PIPP), are 
based on these observations.11–13 These methods might 
not, however, be an appropriate outcome measure for 
neonatal analgesic trials14–16 because they are largely 
based on human observation and judgment,17 and, 
whereas pain experience and pain behaviour are linked 
in adults,18 they might not be linked in neonates. For 
example, infants who do not display a change in facial 
expression after tissue damaging procedures might still 
display signiﬁ cant cortical responses,19 which suggests 
that infant behaviour is not a simple indication of pain 
activity in the brain. Many conditions, such as 
immaturity, neurological damage, and maternal drug 
misuse, can aﬀ ect integrated sensorimotor function and 
consequent behaviour,20–22 but might not necessarily 
aﬀ ect sensory pain processing.
Single heel lances evoke speciﬁ c nociceptive brain 
activity recorded with neonatal electroencephalography 
(EEG)9,23 and spinal nociceptive reﬂ exes recorded with 
electromyography (EMG).24 We undertook a randomised 
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controlled trial of sucrose analgesia with use of this 
speciﬁ c nociceptive brain activity as a direct measure of 
infant pain. 
Methods 
Study design and patients 
We undertook a double-blind randomised study on the 
postnatal ward in the Elizabeth Garrett Anderson and 
Obstetric Wing, University College Hospital (UCH; 
London, UK), between Feb 25, 2009, and March 25, 
2010. The participants were healthy newborn infants, 
born at 37–43 postmenstrual weeks, and less than 
8 days old. 
Medical charts were reviewed and, at the time of study, 
infants were assessed as clinically stable. All infants were 
awake; not receiving analgesic drugs, sedatives, or other 
psychotrophic agents; had not been fed for at least 30 min 
before start of the study; were supine; and were self-
ventilating in air. Infants were not eligible for inclusion in 
the study if they showed signs of tissue damage on the 
lower limbs, had previous surgery, had intraventricular 
haemorrhage or periventricular leukomalacia, were born 
to diabetic mothers or opioid users, were asphyxiated at 
birth, or were born with congenital malformations or 
other genetic disorders. Infants were also excluded if they 
had contraindications to the administration of sucrose: 
high risk for necrotising enterocolitis, feeding intolerance, 
oesophageal atresia or tracheal oesophageal ﬁ stula, or 
active phase persistent pulmonary hypertension. 
Ethics approval was obtained from the UCH ethics 
committee and informed written parental consent was 
obtained before each procedure. The study conformed to 
the standards set by the Declaration of Helsinki and 
Good Clinical Practice guidelines. 
Randomisation and masking
Treatment randomisation and dispensing was done 
oﬀ site at the UCH pharmacy. The pharmacy received 
the sterile sucrose solution (24% sucrose in puriﬁ ed 
water) and sterile water samples from Inspiration 
Healthcare (Respironics, Murrysville, PA, USA) in 
individual 15 mL vials, which could not be visually 
distinguished by the packaging. 60 samples were 
randomised by a block design with a 1:1 allocation for 
sucrose and sterile water. The samples were separated 
into six blocks of ten, in which each block contained 
ﬁ ve sucrose samples and ﬁ ve sterile water samples. The 
pharmacy labelled each sample with a randomisation 
code that corresponded to the identity of the solutions. 
Randomisation was achieved with a computer-generated 
randomisation code. Only the hospital pharmacy had 
access to the randomisation codes that could be used to 
identify the solution. A sealed copy of the randomisation 
chart was also stored in the neonatal unit in case an 
adverse event was reported. Throughout the study the 
researchers, clinicians, participants, and parents were 
masked to the identity of the solutions. Inspiration 
Healthcare was not involved in the study design, data 
collection, or data analysis. No interim analysis was 
done in this study.
Procedures
The noxious stimulus was a heel lance done to collect a 
clinically necessary blood sample. The foot was not 
squeezed for at least 30 s after the heel lance to ensure 
that the recorded responses could be timed from one 
discrete event. This procedure was done without 
impairing the clinical blood collection. No heel lances 
were done solely for the purpose of the study. Before the 
administration of the sucrose or sterile water a non-
noxious control stimulus was applied to the infant’s heel 
with a heel lancet. The lancet was rotated by 90° and 
placed against the heel, so that when the spring-loaded 
blade was released it did not contact the infants’ heel. 
Infants experienced only the non-noxious tactile 
sensation and auditory click that occurs when the blade 
is released. 
The sucrose solution or sterile water was administered 
directly onto the anterior surface of the tongue with a 
1 mL syringe 2 min before a heel lance was done. In line 
with present clinical practice, the dose and expiry date of 
each solution was double-checked by two neonatal 
practitioners, and a neonatal nurse administered all 
solutions. A neonatal nurse was present during the 
studies and was responsible for the clinical care of the 
infants at all times. She was also responsible for reporting 
any adverse events to the consultant in charge. 
Experimental recording techniques
A neonatal EEG cap (WaveGuard EEG cap, Advanced 
NeuroTechnology, Enschede, Netherlands) was used to 
record EEG activity in the infants. 32 recording electrodes 
were positioned according to the modiﬁ ed international 
10/20 electrode placement system at Fz, Fp1, Fp2, F3, F4, 
F7, F8, FT9, FT10, FC5, FC6, Cz, CPz, C3, C4, CP3, CP4, 
CP5, CP6, Pz, POz, P3, P4, P9, P10, PP07, PP08, T7, T8, 
Oz, O1, and O2. Reference and ground electrodes were 
placed at FCz and the chest, respectively. Electrode to 
skin impedance was kept to a minimum by massaging 
the head with an EEG prepping gel before the cap was 
placed on the head. Conductive EEG gel was placed in 
the electrode cups, with a syringe, before the EEG cap 
was placed on the head. The EEG cap was sterilised after 
each study by the UCH Sterile Services Department. 
EEG activity, from 0·05 to 70 Hz, was recorded with 
the Neuroscan (Scan 4.3) SynAmps2 EEG/EP recording 
system (Compumedics US, Charlotte, NC, USA). 
Signals were digitised with a sampling rate of 2 kHz and 
had a resolution of 24 bit. A 50 Hz notch ﬁ lter was used. 
The heel lance was time-locked to the EEG recording 
with an accelerometer attached to the upper surface of 
the lancet.
Respiration was monitored with a movement transducer 
placed on the abdomen and heart rate measured with 
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lead 1 electrocardiograph (ECG) electrodes placed on the 
chest. Oxygen saturation and heart rate were continuously 
measured with a Nellcor N-560 transcutaneous pulse 
oximeter (Covidien-Nellcor and Puritan Bennett 
Boulderm, CO, USA) that was placed on the foot 
contralateral to the site of stimulation. Pulse oximetry 
data were downloaded from the oximeter to a recording 
computer as they were acquired. 
EMG activity, from 1 to 500 Hz, was recorded from the 
ipsilateral biceps femoris muscle with self-adhesive 
bipolar surface silver/silver chloride (Ag/AgCl) electrodes. 
Electrode to skin impedance was reduced by rubbing the 
skin with an EEG prepping gel. Electrodes were secured 
with self-adherent wrap and electrode leads were tied 
together to minimise electrical interference. 
Facial expression was recorded with a portable tripod-
mounted camcorder. A light emitting diode (LED), which 
ﬂ ashed when either the non-noxious control event or 
noxious heel lance was done, was placed in the ﬁ eld of 
view of the camcorder. Figure 1 shows the experimental 
time line.
Outcome measures
The primary outcome measure was pain-speciﬁ c brain 
activity evoked by one time-locked heel lance, recorded 
with EEG and identiﬁ ed by principal component 
analysis (PCA). Secondary measures were baseline 
behavioural and physiological measures, observational 
pain scores (PIPP), and spinal nociceptive reﬂ ex 
withdrawal activity. The primary hypothesis was that 
administration of sucrose 2 min before a heel 
lance would reduce the evoked nociceptive-speciﬁ c 
brain activity.
1500 ms EEG epochs corresponding to a noxious heel 
lance and non-noxious control event were considered for 
analysis (PCA). The EEG epochs included activity recorded 
500 ms before and 1000 ms after each event. The segments 
were referenced to a common average, baseline corrected, 
high-pass ﬁ ltered above 0·5 Hz, and aligned between 400 
and 750 ms to correct for interindividual latency variability 
(maximum –20 to 50 ms). Infants were excluded from the 
analysis if technical failure occurred in the EEG recording 
or if movement artifact—deﬁ ned as a voltage change 
greater than 50 μV over 50 ms in 15 or more electrodes—
was identiﬁ ed in the alignment window.
Nociceptive-speciﬁ c activity was characterised at 
electrode site Cz because we have previously reported 
nociceptive-speciﬁ c activity at this electrode site,9,23 and 
because studies in adults show that similar potentials 
recorded at Cz are sensitive to pharmacological 
analgesic drugs.25
In the original research protocol we intended to use 
peak-to-peak amplitude detection. We deviated from the 
original protocol as instead we used PCA to analyse the 
data. This is an improved analytical technique that has 
been successfully used in EEG analysis and is more robust 
than peak-to-peak amplitude detection because it takes 
into account the overall signal rather than two single data 
points that can be easily aﬀ ected by noise and are diﬃ  cult 
to identify. We have successfully used this method in 
previous work to characterise evoked potentials generated 
after noxious and non-noxious stimulation in the human 
infant brain.9,23
PCA was used to decompose the EEG epochs recorded 
at Cz into basic waveforms, termed principal com-
ponents.26 Epochs were considered as variables and 
timepoints as observations; the resultant covariance 
matrix was selected as the association matrix. The 
principal components represent systematic variation in 
the amplitude of the signal across timepoints in a cluster 
Figure 1: Experimental time line
EEG=electroencephalography. EMG=electromyography.
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Heart rate and oxygen saturation
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Evoked potential 
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Reﬂex limb withdrawal
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Outcome measure
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of epochs. The extent to which each component is 
represented in an individual EEG epoch is quantiﬁ ed by 
a unique weight. The weights of the ﬁ rst two principal 
components, which accounted for 84% of the total 
variance, were considered for analysis. 
The PIPP score was calculated for each infant on the 
basis of behavioural and physiological observations.12 
The facial expression component of the PIPP was 
analysed by trained observers (two neonatal research 
nurses) watching the videos for 30 s immediately after 
the heel lance. The videos were cut into 45 s epochs, 
which included 15 s before stimulus and 30 s after 
stimulus. The presence of each facial expression 
(nasolabial furrow, eye squeeze, and brow bulge) was 
assessed individually. The number of infants who had a 
facial expression score of zero was also calculated.22 The 
observers were fully masked to the treatment allocation 
and stimulus type when they analysed the videos. The 
observers did not know whether they were viewing video 
footage after the heel lance or the control stimulation. 
An additional level of masking was imposed by mixing 
the videos with other non-trial video footage. The facial 
expression component of the PIPP was rescored by two 
observers in 15 of 60 (25%) of the videos to assess intra-
rater and inter-rater reliability, which was analysed by 
the Bland-Altman method.27 Bland-Altman plots showed 
good reliability with little bias (intra-rater bias 0·07; 
inter-rater bias 0·73). The limits of agreement for the 
intra-rater re-test were ±1·62. The limits of agreement 
for the inter-rater comparison were ±1·49.
The mean heart rate and oxygen saturation in the 15 s 
before the heel lance, and the maximum heart rate and 
the minimum oxygen saturation in the 30 s after the heel 
lance were used to calculate the physiological indices in 
the PIPP score. Custom-made data analysis software, 
written in MATLAB, was used to automatically calculate 
the mean baseline heart rate and oxygen saturation. The 
software also calculated change in heart rate and oxygen 
saturation from the heel lance. The data used these 
parameters to automatically calculate the physiological 
indices in the PIPP score. 
The behavioural state score was calculated by observing 
the infant’s sleep state and facial movements on the video 
footage in the 15 s before the heel lance. The latency to 
facial expression change was deﬁ ned as the latency when 
the ﬁ rst PIPP facial feature (ie, nasolabial furrow, eye 
squeeze, and brow bulge) was observed after the heel 
lance in each infant.22
EMG analysis
2500 ms EMG epochs corresponding to a noxious heel 
lance were considered for analysis. The EMG epochs 
included activity recorded 1000 ms before and 1500 ms 
after each event. The segments were high-pass ﬁ ltered 
above 10 Hz and rectiﬁ ed. Latency to ﬂ exion withdrawal 
reﬂ ex activity was deﬁ ned as the time after stimulus 
when the EMG activity exceeded three standard 
deviations of the pre-stimulus baseline. Magnitude of 
ﬂ exion withdrawal reﬂ ex activity was measured in 
250 ms periods after stimulus by calculation of the root 
mean square activity. The summary parameter for the 
magnitude of the spinal nociceptive reﬂ ex EMG activity 
was deﬁ ned as the root mean square activity in 1000 ms 
after stimulus. Infants were not included in the EMG 
analysis when technical failure occurred in the 
EMG recording.
Statistical analysis
Data were analysed according to the trial protocol. A 
sample size of 40 infants had greater than 80% power to 
Figure 2: Trial proﬁ le
EEG=electroencephalography. PIPP=premature infant pain proﬁ le. EMG=electromyography.
94 eligible infants
35 excluded
32 parents refused to participate
1 clinical heel lance procedure cancelled
1 equipment unavailable
1 drug unusable
30 assigned to receive sterile water
30 received sterile water as assigned
1 withdrawn (parent withdrew consent)
24 included in EEG and PIPP analysis
5 excluded from EEG and PIPP analysis
1 technical failure
4 movement artifact in the EEG
15 included in EMG analysis
9 excluded from EMG analysis
2 no EMG recording
7 technical failure
29 assigned to receive sucrose
29 received sucrose as assigned
0 withdrawn
20 included in EEG and PIPP analysis
9 excluded from EEG and PIPP analysis
1 unable to score video facial expression
2 unable to use pulse oximetry data
3 technical failure
3 movement artifact in the EEG
19 included in EMG analysis
1 excluded from EMG analysis
1 no EMG recording
59 randomised
Sucrose 
(N=20)
Sterile water 
(N=24)
PMA at birth (weeks) 39·8 (1·1) 39·8 (1·3)
PMA at time of study (weeks) 40·1 (1·1) 40·3 (1·4)
Postnatal age at time of study (days) 3 (2) 3 (2)
Birthweight (g) 3449 (453) 3454 (443)
Boys 11/20 (55%) 15/24 (63%)
Apgar score at 1 min 8·2 (1·5) 8·0 (1·9)
Spontaneous vaginal delivery 8/20 (40%) 11/24 (46%)
Right heel lanced 13/20 (65%) 12/24 (50%)
Data are mean (SD) or n/N (%). PMA=postmenstrual age.
Table 1: Characteristics of participating neonates
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detect a 30% reduction in the amplitude of the nociceptive-
speciﬁ c brain activity as signiﬁ cant (p<0·05; two-tailed). 
We allowed for a total sample size of 60 infants (30 per 
group) to account for a high number of anticipated losses 
(ten per group) because of the possibility that technical 
failure could occur in any one of the physiological 
recordings (ie, video, EEG, or pulse oximetry; typically 
20%; four per group) and that movement artifact could be 
recorded in the EEG (typically 20%; four per group).
Two-way nested analysis of variance was applied to the 
principal component weights to assess  the eﬀ ect 
of  stimulation type (non-noxious control, noxious heel 
lance) and treatment (sterile water, sucrose). With this 
analysis we assessed whether noxious stimulation 
generated a speciﬁ c component and whether this 
component was aﬀ ected by sucrose or sterile water 
administration. Nociceptive-speciﬁ c brain activity was 
identiﬁ ed by measurement of the principal components 
whose weights were signiﬁ cantly greater after the noxious 
lance compared with non-noxious control.
As with our previous publications, only one nociceptive-
speciﬁ c principal component was identiﬁ ed. To ensure 
that the activity deﬁ ned in our participant sample could 
be generalised to other external samples, we compared 
the evoked activity with that reported in a previously 
published dataset9 and calculated the correlation 
coeﬃ  cient between the observations. Two-way nested 
analysis of variance was applied in the same way to the 
root mean square values of the EMG reﬂ ex activity.
The eﬀ ect of the treatment on all other outcome 
measures was summarised as mean values (with 
95% CIs) and signiﬁ cance of the diﬀ erences tested with 
unpaired Student’s t tests. A signiﬁ cance level of 0·05 
was used in all the tests. Data were analysed with 
MATLAB (version 7.8.0). 
This study is registered, number ISRCTN78390996.
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Figure 2 shows the trial proﬁ le. There were no deviations 
from the inclusion and exclusion criteria. 59 infants were 
included in our initial sample, of whom 44 were included 
in the ﬁ nal analysis. Table 1 shows the characteristics of 
the ﬁ nal population of infants. After sucrose or sterile 
water administration the mean heart rate, oxygen 
saturation, and behavioural scores in the 15 s before the 
heel lance did not diﬀ er signiﬁ cantly between infants 
who were given sucrose and those given sterile water 
(table 2). 
After the heel lance, the PIPP score was signiﬁ cantly 
lower in infants who were given sucrose than in those 
given sterile water; however, we recorded no signiﬁ cant 
diﬀ erence in the latency to change in facial expression 
between the two treatment groups (table 2). The number 
of infants who had a zero facial expression score after the 
noxious heel lance was signiﬁ cantly higher in the sucrose 
group than in the sterile water group (table 2). 
Nociceptive-speciﬁ c brain activity was identiﬁ ed by one 
principal component that was signiﬁ cantly greater after 
the heel lance (mean principal component weight 0·09 
[SE 0·02]) than after the non-noxious control event (0·03 
[0·01]; p=0·006; ﬁ gure 3A). The correlation coeﬃ  cient 
between this component and a nociceptive-speciﬁ c 
component calculated in an external sample of term 
infants in a previously published study9 was 92% 
(p<0·0001). The nociceptive-speciﬁ c brain activity did not 
diﬀ er signiﬁ cantly between infants who received sucrose 
(mean principal component weight 0·10 [SE 0·03]) and 
those who received sterile water (0·08 [0·02]; p=0·46; 
ﬁ gure 3B). 
Spinal reﬂ ex withdrawal activity, recorded by EMG of 
the biceps femoris of the stimulated leg, was signiﬁ cantly 
greater after the heel lance (mean activity 33·78 μV 
[SE 4·02] than after the non-noxious control event 
Sucrose (N=20) Sterile water (N=24) p value
Primary outcome
Nociceptive-speciﬁ c brain activity (mean weight) 0·10 (0·04–0·16) 0·08 (0·04–0·12) 0·46
Secondary outcomes    
Mean baseline heart rate (bpm) 132·6 (124·3–140·9) 131·8 (122·2–141·5) 0·90
Mean baseline oxygen saturation (%) 99·4% (98·8–100·1) 97·4% (95·0–99·8) 0·13
Baseline behavioural score (from PIPP) 1·3 (0·8–1·7) 1·3 (0·8–1·8) 0·91
PIPP score 5·8  (3·7–7·8) 8·5 (7·3–9·8) 0·02
Latency to change in facial expression (s) 3·8 (1·3–6·4) 3·5 (1·0–6·1) 0·86
Facial non-responders 7/20 (35%) 0/24 (0%) <0·0001
Mean nociceptive reﬂ ex withdrawal activity (μV) 36·11 (24·20–48·02) 30·82 (18·51–43·13) 0·49
Mean latency to nociceptive reﬂ ex withdrawal activity (ms) 363·3 (256·4–470·1) 413·5 (262·0–564·9) 0·56
Data are mean (95% CI) or n/N (%). bpm=beats per min. PIPP=premature infant pain proﬁ le.
Table 2: Primary and secondary outcomes
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(8·84 μV [3·67]; p<0·0001; ﬁ gure 4A). The magnitude of 
the spinal reﬂ ex withdrawal activity did not diﬀ er 
signiﬁ cantly between infants who received sucrose (mean 
activity 36·11 μV [SE 5·67]) and those who received sterile 
water (30·82 μV [5·74]; p=0·49; ﬁ gure 4B). Furthermore, 
mean latency to nociceptive reﬂ ex withdrawal activity did 
not diﬀ er signiﬁ cantly between the two groups (table 2). 
No adverse events were recorded during this study.
Discussion
This randomised controlled trial measured the eﬀ ect of 
oral sucrose on procedural pain in infants, with direct 
measures of brain and spinal cord activity as an outcome 
measure for pain. The results show that although, as 
previously reported, sucrose signiﬁ cantly reduces the 
PIPP score—a composite observational behavioural and 
physiological measure2—it has no eﬀ ect on the neural 
activity in sensory pain circuits in the brain or the spinal 
cord. Although true pain perception cannot be measured 
in non-verbal populations, neural activity in nociceptive 
pathways is a more direct measure than behavioural and 
physiological assessment. The ﬁ nding that sucrose does 
not change neural activity strongly suggests that pain 
perception is not aﬀ ected by this intervention. 
Any measure of pain in this group is necessarily indirect, 
and whether the electrophysiological measures reported 
in this study are indicative of the conscious pain experience 
of the newborn infant cannot be shown. Nevertheless, 
behavioural and physiological output measures need 
integration and control of several somatic motor and 
autonomic circuits, which are aﬀ ected by several 
developmental homoeostatic and external factors.10,19–21 By 
comparison, the nociceptive-evoked activity in the brain 
and spinal sensory circuits recorded in this study are a 
more direct measure of pain activity in the infant CNS. In 
the adult brain, the magnitude of nociceptive-evoked 
potentials directly correlates with perceived pain 
intensity.28,29 The nociceptive-evoked activity in ﬂ exor 
muscles, which cause reﬂ ex withdrawal of the limb, is also 
a proven functional measure of spinal and supraspinal 
pain processing.30 Pharmacological analgesic drugs, such 
as tramadol and morphine, depress nociceptive-evoked 
brain activity and ﬂ exion reﬂ exes, and result in concurrent 
reduction in perceived pain intensity in adults.25,31,32
Our results accord with previous trials showing that 
sucrose decreases infant PIPP scores,2 but they show that 
such scores do not reliably reﬂ ect nociceptive activity in 
the brain of newborn infants, possibly because of the site 
of action of sucrose in the brain. The reduction in 
nociceptive behaviour recorded after oral sucrose in 
young rats33 persists after midbrain transection, 
suggesting that forebrain neural circuits are not needed 
for this eﬀ ect.34 Sucrose reduction of nociceptive 
withdrawal reﬂ exes in adult rats—a conditioned eﬀ ect of 
all hedonistic foods thought to prevent eating from 
ending—also involves brainstem endogenous inhibitory 
mechanisms.35 Thus in infants exposed to noxious 
procedures, sucrose could mediate a brainstem inhibition 
Figure 3: Characterisation of the nociceptive-speciﬁ c brain activity (A) and eﬀ ect of sucrose or sterile water on the nociceptive-speciﬁ c brain activity (B)
(A) Average waveform of the group data after (i) noxious heel lance and (ii) non-noxious control stimulus (alignment window 400–750 ms). (iii) Mean (SE) weight of 
the second principal component after the noxious heel lance and non-noxious control stimulus (*p=0·006). (B) Average waveform of the group data after the 
noxious heel lance, separated into two groups: (i) infants administered sucrose and (ii) infants administered sterile water (alignment window 400–750 ms). (iii) Mean 
(SE) weight of the nociceptive-speciﬁ c component in the sucrose and sterile water groups (p=0·46).
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of behaviour, and inhibit facial motor activity, while 
strong pain activation still occurs in the forebrain. This 
notion is especially important in view of the increasing 
evidence for short-term and long-term adverse eﬀ ects of 
infant pain experience on neurodevelopment.5–9 The 
absence of evidence for an analgesic action of sucrose in 
this study, together with uncertainty over the long-term 
beneﬁ ts of repeated sucrose administration,36 suggest 
that sucrose should not be used routinely for procedural 
pain in infants without further investigation. 
This double-blind randomised controlled trial used 
new electrophysiological methods to assess the 
eﬀ ectiveness of analgesic drugs in newborn infants. The 
conclusions that we can draw from this study are limited 
by the small sample size (n=44), which could mean that 
this study was not powered to observe subtle eﬀ ects that 
sucrose might have on CNS processing. Signiﬁ cant 
group diﬀ erences in infant nociceptive brain activity 
have, however, been recorded in sample sizes of only 
15 infants.9 This single-centre trial should be repeated in 
a larger sample of infants, and this new method used to 
test the eﬀ ect of other known pharmacological analgesic 
drugs, such as morphine. 
In conclusion, our results show that although oral 
sucrose does reduce observed pain behaviour, it has no 
signiﬁ cant eﬀ ect on the magnitude of spinal nociceptive 
reﬂ exes or on the acute activation of pain networks in 
the brain. Sucrose seems to blunt facial expression 
activity after painful procedures, but our data suggest 
that it does not reduce direct nociceptive activity in 
central sensory circuits, and therefore might not be an 
eﬀ ective analgesic drug. 
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Figure 4: Characterisation of the spinal nociceptive reﬂ ex withdrawal activity (A) and eﬀ ect of sucrose or sterile water on spinal nociceptive reﬂ ex 
withdrawal activity (B)
(A) Example spinal reﬂ ex withdrawal activity in one infant after: (i) noxious heel lance and (ii) non-noxious control stimulus. (iii) Magnitude (mean [SE]) of the spinal 
reﬂ ex withdrawal activity after noxious heel lance and non-noxious control stimulus represented as the root mean square (RMS) activity in 250 ms time periods in 
infants. (iv) Mean (SE) spinal reﬂ ex withdrawal activity in infants after the noxious heel lance and non-noxious control stimulus (*p<0·0001). (B) Example spinal 
nociceptive reﬂ ex withdrawal activity after a noxious heel lance in two infants who received: (i) sucrose and (ii) sterile water. (iii) Magnitude (mean [SE]) of the spinal 
nociceptive reﬂ ex withdrawal activity after noxious heel lance in infants given sucrose or sterile water represented as the RMS activity in 250 ms time periods. (iv) 
Mean (SE) spinal nociceptive reﬂ ex withdrawal activity in infants given sucrose or sterile water (p=0·49).
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